Skip to main content
Moderna, Inc. logo

Moderna, Inc. — Investor Relations & Filings

Ticker · MRNA ISIN · US60770K1079 LEI · 549300EI6OKH5K5Q2G38 US Manufacturing
Open in API
Filings indexed 1,448 across all filing types
Latest filing 2020-02-10 Capital/Financing Update
Country US United States of America
Listing US MRNA

About Moderna, Inc.

https://www.modernatx.com/

Moderna, Inc. is a biotechnology company pioneering the development of messenger RNA (mRNA) therapeutics and vaccines. The company's core platform utilizes mRNA to carry instructions that direct the body's cells to produce proteins, thereby preventing or treating diseases. This technology enables the rapid design, research, and production of new medicines. Moderna is widely recognized for developing one of the first COVID-19 vaccines. Its research and development pipeline extends to various therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, and autoimmune disorders. The company's mission is to create a new generation of transformative medicines for patients by leveraging the potential of its mRNA platform.

Recent filings

Filing Released Lang Actions
S-3ASR Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Moderna, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities such as common stock, preferred stock, debt securities, warrants, and units. The document includes a prospectus describing the securities and the general terms of the offering. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or management discussion. It is also not a proxy statement, voting results, or a legal proceeding report. The document is a regulatory filing related to capital raising and securities registration. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to clear identification of the form and content.
2020-02-10 English
424B5 Filing
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement related to a $500 million common stock offering by Moderna, Inc. It includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and legal matters. The text references SEC registration statements and filings, typical of capital raising documents. The presence of underwriting details, offering price, and the nature of the document as a supplement to a prospectus clearly indicate this is a capital/financing update related to a securities offering. It is not an annual or quarterly report, earnings release, or any other type of report. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content support a high confidence level.
2020-02-10 English
FWP Filing
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus filed pursuant to Rule 433, relating to a Preliminary Prospectus Supplement. It discusses Moderna's vaccine development progress, clinical trial phases, and new vaccine candidates. The content focuses on investment and financing information related to Moderna's vaccine pipeline and clinical progress, typical of a capital markets communication. It is not a full financial report, earnings release, or regulatory filing of financial results. The document is a detailed announcement related to fundraising and investment, consistent with a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-02-10 English
FWP Filing
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus filed pursuant to Rule 433, relating to a Preliminary Prospectus Supplement and Registration No. 333-236348. It announces clinical trial enrollment and provides detailed information about the drug candidate mRNA-3704, its study design, and regulatory designations. The document is a communication related to a securities offering, typical of a prospectus supplement or free writing prospectus used in capital markets to inform investors about the offering and related developments. It is not a financial report, earnings release, management discussion, or regulatory filing in the usual sense, but rather a capital markets disclosure related to fundraising. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to clear identification of the document type and content.
2020-02-10 English
4 Filing
Director's Dealing
2020-02-04 English
4 Filing
Director's Dealing
2020-02-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.